February 09, 2017

Icosagen identified several high-risk HPV inhibitors and drug targets with a novel high-throughput screening assay

Genetically engineered HPV genomes enable identification of potential drug targets and candidates  Scientists have used genetic engineering techniques to develop a new system that could aid identification of potential drug targets and treatments for human papillomavirus (HPV) infection, according to a PLOS Pathogens study.
Read more ›

December 29, 2016

Meet us at PEPTalk 2017

Icosagen will be attending the 16th annual PepTalk conference held in San Diego on January 9-13th, 2017. Come visit us at our booth, #305, and we will be more than happy to accommodate you with both information and insight to our protein and antibody production capabilities.Our CSO, Meelis Kadaja, will be presenting about: “A Stable Episomal Expression System to Streamline Antibody Production” on Jan 12 at 3:05pm in the Antibody Therapeutics track.
Read more ›

December 19, 2016

Merry christmas!

Read more ›

May 05, 2016

Icosagen AS donates to SA University of Tartu Clinic's Children foundation

SA University of Tartu Clinic in partnership with Club Tartu Marathon started in 2013 a charity sport event "Heateo jooks". SynLab, Sirowa, Nutri Kaubanduse, Icosagen AS and Uus Apteek all collectively donate 5€ for every  attendee to support children with joint disease and weight problems. The run is held at 6th of may and donations are gathered for 3 year old Cassandra with Epidermolysis bullosa (EB). Read more about the eventRead more at Children foundation (in estonian)
Read more ›

April 01, 2016

Icosagen developed anti-human BNDF antibody clone 3C11 played prominent role in Neuroscience and JBC publications.

In March, 2016 two research groups published their results in Neuroscience and JBC using Icosagen-developed anti-human BDNF antibody.
Read more ›

April 01, 2016

HORIZON 2020 project: PROFILE Innovative Training Network

Icosagen AS is participating as beneficiary in Horizon 2020 project: PROFILE Innovative Training Network.
Read more ›

February 29, 2016

Press release: Icosagen Cell Factory was awarded EUR 1.2 million

January 11, 2016

HybriFree recombinant antibody development article is published

December 18, 2015

Seasons Greetings

September 17, 2015

Icosagen AS has incorporated a US subsidiary – Icosagen Technologies, Inc.

September 04, 2015

Icosagen Cell Factory is participating in 29th NIH Research Festival, September 16-18, 2015 in Bethesda, USA

September 04, 2015

Icosagen Cell Factory is participating first MANF and CDNF Proteins Symposium, September 14-15, San Francisco, California

June 10, 2015

Icosagen Cell Factory is participating in AACC Meeting, July 26–30, Georgia World Congress Center, Atlanta, Georgia

June 10, 2015

Icosagen Cell Factory is participating in the BIO International Convention, June 15-18, 2015, Philadelphia

December 30, 2014

The Icosagen Cell Factory OÜ team is looking for a MARKETING SPECIALIST

December 22, 2014

QMCF Technology to be presented at the CHI's 14th Annual PepTalk conference in San Diego, California

December 19, 2014

Happy Holidays from Icosagen!

October 15, 2014

Icosagen and FIT Biotech Oy begin cooperation to develop anti-ebola vaccines and biological therapeutics

October 02, 2014

Icosagen Cell Factory was titled the Best Entrepreneur of 2013

September 08, 2014

Icosagen's opening ceremony

June 10, 2014

QMCF Technology based CHO/Furin expression cell line is available

May 02, 2014

Icosagen Cell Factory attends to PEGS 2014 in Boston

February 05, 2014

Icosagen Cell Factory presentation at Cell Line Development Conference

February 03, 2014

New premises of Icosagen Group